WATERTOWN, Mass.–(BUSINESS WIRE)–Aug. 8, 2019– Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the…Original Article
Kala Pharmaceuticals Receives FDA Complete Response Letter for KPI-121 0.25% NDA and Plans to Respond with Data From STRIDE 3 Trial
